The largest community of pharma leaders

Phillips-Medisize Announces the Appointment of Paul Chaffin as Senior Vice President and President, Medical and Pharmaceutical Solutions, Molex

HUDSON, Wis.–()–Phillips-Medisize, a Molex company, announced the appointment of Paul Chaffin as Senior Vice President and President of the Medical and Pharmaceutical Solutions division of Molex. In his new role, Chaffin will provide global vision, leadership, and strategic direction to drive profitable, long-term growth for Molex’s Medical and Pharmaceutical Solutions portfolio, which includes Phillips-Medisize – an end-to-end provider of innovation, development, and manufacturing solutions to the pharmaceutical, diagnostics and medical device market segments. Chaffin will report to Joe Nelligan, Chief Executive Officer of Molex, and will be a member of the company’s Global Leadership Team.

“Paul’s depth of healthcare, commercial and international experience combined with his strong leadership skills will be a big asset to not only our medical business but to the Molex leadership team. We’re confident that Paul will help fulfill our vision of expanding our global footprint with innovative and digitally connected medical solutions at a time when delivering top-quality care to patients around the world is so critical,” said Joe Nelligan, CEO of Molex.

“The combined capabilities of Phillips-Medisize, Molex and Koch to drive the innovation necessary to transform the diagnosis and delivery of healthcare is an unparalleled opportunity to help improve the lives of people around the world,” Chaffin added. “I’m looking forward to working with a global team of passionate people who are driven to solve complex problems that help patients lead longer, more productive lives.”

Chaffin joins Molex from a Minnesota-based Fortune 500 company, where he was most recently Senior Vice President of Strategic Initiatives. Prior to this role, he spent 11 years building and leading the company’s global healthcare and life science business.

He has a BA and an MBA from the University of Michigan. He also has served on several Boards and Advisory Councils including Medical Alley and the Joint Commission’s Center for Transforming Healthcare. He lives in Minnesota and will be based in the Phillips-Medisize Hudson, Wisconsin office.

About Phillips-Medisize:

Phillips-Medisize, LLC, a Molex company, is an end-to-end provider of innovation, development, and manufacturing solutions to the pharmaceutical, diagnostics, and medical device market segments. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize’s core advantage is the knowledge of its people to integrate design, molding, electronics, and automation, providing innovative, high-quality manufacturing solutions. For more information, please visit www.phillipsmedisize.com or www.molex.com.

Source

Recent Articles

AVROBIO to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene...

Global Neurofibromatosis Treatment Drugs Market to Surpass US$ 21,223.7 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE--(BUSINESS WIRE)-- #NeurofibromatosisTreatment--The Asia Pacific is expected to witness significant growth...

FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the US Food...

Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced today initiatives to bring attention to...

Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Receives ADLT Status for Envisia Genomic...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.